Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC By Ogkologos - August 31, 2026 37 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the third pre-specified interim analysis of the OlympiA study Source RELATED ARTICLESMORE FROM AUTHOR NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer MOST POPULAR Intracranial Efficacy of Pembrolizumab in Patients with Brain Metastases June 20, 2023 Patient Guide in Bladder Cancer Now Available Also in French April 28, 2026 FDA Approves Pralsetinib for RET-Altered Thyroid Cancers December 2, 2020 Coronavirus reports – Part 10: “I didn’t see my mum before... September 15, 2021 Load more HOT NEWS Nomination Process for the 2026 ESMO Society Awards Now Open Resilience Isn’t About Bouncing Back Adjuvant Chemotherapy Customisation Based on ERCC1 and TS mRNA Levels Does... Blind Customer Surprised With Sweet Message In Braille For Her Birthday
